If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is there an Emgality® (galcanezumab-gnlm) pregnancy registry?
An Emgality (galcanezumab) pregnancy registry is currently available in the United States. Eligible women may self-enroll or be enrolled by their healthcare provider into the Lilly Migraine Pregnancy Registry by contacting 1-833-464-4724.
A pregnancy exposure registry in the United States will compare maternal, fetal, and infant outcomes among pregnant women with migraine exposed to galcanezumab to those exposed or not exposed to other migraine medications.1
This study will enroll mothers with live births into each of the following groups:
- women with migraine exposed to galcanezumab up to 5 months before or during pregnancy
- pregnant women with migraine exposed to other migraine preventative medications, and
- pregnant women with migraine not exposed to migraine preventative medications.1
Eligible women may self-enroll or be enrolled by their healthcare provider into the Lilly Migraine Pregnancy Registry by contacting 1-833-464-4724.1 This registry is only available in the United States.
Pregnancy or related events can be reported to
- the Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov/medwatch, or
- Eli Lilly and Company at 1-800-LILLYRX (1-800-545-5979).
Enclosed Prescribing Information
1Ephross SA, Schroeder KM, Kellier-Steele NA, et al. Registry-based, prospective, observational study to assess maternal, fetal, and infant outcomes following exposure to migraine treatments, including galcanezumab. Poster presented at: Diamond Headache Clinic Research & Educational Foundation; July 15-18, 2021; Lake Buena Vista, FL.
Date of Last Review: July 19, 2021